A phase II study of tipifarnib and gemcitabine in metastatic breast cancer.

Invest New Drugs 2018 04 27;36(2):299-306. Epub 2018 Jan 27.

Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Dan L. Duncan Building, CPB5.3542, 1515 Holcombe Blvd., Unit 1354, Houston, TX, 77030, USA.

Background Tipifarnib is an orally active, competitive inhibitor of farnesyltransferase which has shown encouraging signs of activity either alone or when combined with other agents. Clinical studies of tipifarnib in combination with anti-estrogen therapy have yielded disappointing results. In contrast, tipifarnib appears to be synergistic in combination with anthracycline based chemotherapy. Here we report the results of the first prospective phase II trial evaluating the efficacy of the novel combination of tipifarnib and gemcitabine in the treatment of metastatic breast cancer. Patients and Methods 30 postmenopausal women with metastatic breast cancer were treated on a 21-day cycle with tipifarnib 300 mg PO twice daily from days 1 through 14. Gemcitabine was administered intravenously at a dose of 1000 mg/m on days 1 and 8. Patients were treated until disease progression or unacceptable toxicity. Results There was one complete response and four partial responses yielding an objective response rate of 16.7%. Median progression-free survival and overall survival was 2.5 months (95% confidence interval: 1.6-5.7 months) and 13.1 months (95% confidence interval: 9.1-20.6 months), respectively. 40% of patients experienced grade 4 neutropenia in this study. Conclusion The combination of tipifarnib and gemcitabine is not well tolerated with high rates of myelosuppression and is not more effective than gemcitabine monotherapy in the treatment of metastatic breast cancer.

Download full-text PDF

Source
http://link.springer.com/10.1007/s10637-018-0564-2
Publisher Site
http://dx.doi.org/10.1007/s10637-018-0564-2DOI Listing
April 2018
43 Reads

Publication Analysis

Top Keywords

metastatic breast
16
breast cancer
16
tipifarnib gemcitabine
12
confidence interval
8
95% confidence
8
combination tipifarnib
8
treatment metastatic
8
tipifarnib
7
gemcitabine
5
1000 mg/m days
4
days patients
4
patients treated
4
administered intravenously
4
intravenously dose
4
dose 1000 mg/m
4
progression unacceptable
4
toxicity complete
4
complete response
4
response partial
4
unacceptable toxicity
4

References

(Supplied by CrossRef)

DW End et al.
Cancer Res 2001

K Kato et al.
Proc Natl Acad Sci U S A 1992

LR Kelland et al.
Clin Cancer Res 2001

E Izbicka et al.
Anticancer Res 2005

F Warnberg et al.
Breast Cancer Res 2006

M Caraglia et al.
Front Biosci 2005

F Dalenc et al.
Breast Cancer Res 2005

LA Martin et al.
Mol Cancer Ther 2007

ME Balasis et al.
Clin Cancer Res 2011

GJ Clark et al.
Breast Cancer Res Treat 1995

SR Johnston et al.
J Clin Oncol 2003

Similar Publications